Effect of concomitant use of yokukansan on steady‐state blood concentrations of donepezil and risperidone in real‐world clinical practice
Abstract Aim Yokukansan is one of the most frequently used herbal medicines that can improve the behavioral and psychological symptoms of dementia. In this exploratory study, we investigated whether yokukansan affects the steady‐state blood concentrations of donepezil, risperidone, and the major met...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-09-01
|
| Series: | Neuropsychopharmacology Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/npr2.12459 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846173738552262656 |
|---|---|
| author | Junji Saruwatari Tetsuya Kaneko Tsukasa Murata Haruka Narise Sawa Kugimoto Eri Nishimura Natsuki Tetsuka Misaki Ando Momo Oi Masako Ota Nayumi Hamada Keiichiro Kaneda Shiro Furusho Masakatsu Sakamoto Ayami Kajiwara‐Morita Kazutaka Oda Kentaro Oniki Keishi Ueda Hirofumi Jono Norio Yasui‐Furukori |
| author_facet | Junji Saruwatari Tetsuya Kaneko Tsukasa Murata Haruka Narise Sawa Kugimoto Eri Nishimura Natsuki Tetsuka Misaki Ando Momo Oi Masako Ota Nayumi Hamada Keiichiro Kaneda Shiro Furusho Masakatsu Sakamoto Ayami Kajiwara‐Morita Kazutaka Oda Kentaro Oniki Keishi Ueda Hirofumi Jono Norio Yasui‐Furukori |
| author_sort | Junji Saruwatari |
| collection | DOAJ |
| description | Abstract Aim Yokukansan is one of the most frequently used herbal medicines that can improve the behavioral and psychological symptoms of dementia. In this exploratory study, we investigated whether yokukansan affects the steady‐state blood concentrations of donepezil, risperidone, and the major metabolites of both drugs in a real‐world clinical setting. Methods A non‐randomized, open‐label, single‐arm study examining drug–drug interactions was conducted. Fifteen dementia patients taking donepezil for at least 4 weeks and eight schizophrenia patients taking risperidone for at least 2 weeks were orally administered 2.5 g of yokukansan three times a day before or between meals, and blood samples were collected before and 8 weeks after starting co‐treatment with yokukansan. Plasma concentrations of donepezil, risperidone, and each metabolite were measured using high‐performance liquid chromatography–tandem mass spectrometry and compared before and after the 8‐week administration of yokukansan. Results The plasma concentrations of donepezil and its metabolites (6‐O‐desmethyl‐donepezil, 5‐O‐desmethyl‐donepezil, and donepezil‐N‐oxide), risperidone, and its metabolite paliperidone did not differ before and after the 8‐week treatment with yokukansan. Conclusions The findings of this study show that the concomitant use of yokukansan may have little clinical impact on the steady‐state blood levels of donepezil and risperidone in patients with dementia or schizophrenia. |
| format | Article |
| id | doaj-art-386f5c7aa74645a3abe2bcb297fffb71 |
| institution | Kabale University |
| issn | 2574-173X |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Neuropsychopharmacology Reports |
| spelling | doaj-art-386f5c7aa74645a3abe2bcb297fffb712024-11-08T11:46:40ZengWileyNeuropsychopharmacology Reports2574-173X2024-09-0144361461910.1002/npr2.12459Effect of concomitant use of yokukansan on steady‐state blood concentrations of donepezil and risperidone in real‐world clinical practiceJunji Saruwatari0Tetsuya Kaneko1Tsukasa Murata2Haruka Narise3Sawa Kugimoto4Eri Nishimura5Natsuki Tetsuka6Misaki Ando7Momo Oi8Masako Ota9Nayumi Hamada10Keiichiro Kaneda11Shiro Furusho12Masakatsu Sakamoto13Ayami Kajiwara‐Morita14Kazutaka Oda15Kentaro Oniki16Keishi Ueda17Hirofumi Jono18Norio Yasui‐Furukori19Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences Kumamoto University Kumamoto JapanDivision of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences Kumamoto University Kumamoto JapanKumamoto Seimei Hospital Kumamoto JapanDivision of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences Kumamoto University Kumamoto JapanDivision of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences Kumamoto University Kumamoto JapanDivision of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences Kumamoto University Kumamoto JapanDepartment of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences Kumamoto University Kumamoto JapanDepartment of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences Kumamoto University Kumamoto JapanDepartment of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences Kumamoto University Kumamoto JapanDepartment of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences Kumamoto University Kumamoto JapanKumamoto Seimei Hospital Kumamoto JapanKumamoto Seimei Hospital Kumamoto JapanKumamoto Seimei Hospital Kumamoto JapanKumamoto Seimei Hospital Kumamoto JapanDivision of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences Kumamoto University Kumamoto JapanDepartment of Pharmacy Kumamoto University Hospital Kumamoto JapanDivision of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences Kumamoto University Kumamoto JapanKumamoto Seimei Hospital Kumamoto JapanDepartment of Pharmacy Kumamoto University Hospital Kumamoto JapanDepartment of Psychiatry, School of Medicine Dokkyo Medical University Tochigi JapanAbstract Aim Yokukansan is one of the most frequently used herbal medicines that can improve the behavioral and psychological symptoms of dementia. In this exploratory study, we investigated whether yokukansan affects the steady‐state blood concentrations of donepezil, risperidone, and the major metabolites of both drugs in a real‐world clinical setting. Methods A non‐randomized, open‐label, single‐arm study examining drug–drug interactions was conducted. Fifteen dementia patients taking donepezil for at least 4 weeks and eight schizophrenia patients taking risperidone for at least 2 weeks were orally administered 2.5 g of yokukansan three times a day before or between meals, and blood samples were collected before and 8 weeks after starting co‐treatment with yokukansan. Plasma concentrations of donepezil, risperidone, and each metabolite were measured using high‐performance liquid chromatography–tandem mass spectrometry and compared before and after the 8‐week administration of yokukansan. Results The plasma concentrations of donepezil and its metabolites (6‐O‐desmethyl‐donepezil, 5‐O‐desmethyl‐donepezil, and donepezil‐N‐oxide), risperidone, and its metabolite paliperidone did not differ before and after the 8‐week treatment with yokukansan. Conclusions The findings of this study show that the concomitant use of yokukansan may have little clinical impact on the steady‐state blood levels of donepezil and risperidone in patients with dementia or schizophrenia.https://doi.org/10.1002/npr2.12459drug interactionsherb‐drug interactionsKampometabolismpharmacokinetics |
| spellingShingle | Junji Saruwatari Tetsuya Kaneko Tsukasa Murata Haruka Narise Sawa Kugimoto Eri Nishimura Natsuki Tetsuka Misaki Ando Momo Oi Masako Ota Nayumi Hamada Keiichiro Kaneda Shiro Furusho Masakatsu Sakamoto Ayami Kajiwara‐Morita Kazutaka Oda Kentaro Oniki Keishi Ueda Hirofumi Jono Norio Yasui‐Furukori Effect of concomitant use of yokukansan on steady‐state blood concentrations of donepezil and risperidone in real‐world clinical practice Neuropsychopharmacology Reports drug interactions herb‐drug interactions Kampo metabolism pharmacokinetics |
| title | Effect of concomitant use of yokukansan on steady‐state blood concentrations of donepezil and risperidone in real‐world clinical practice |
| title_full | Effect of concomitant use of yokukansan on steady‐state blood concentrations of donepezil and risperidone in real‐world clinical practice |
| title_fullStr | Effect of concomitant use of yokukansan on steady‐state blood concentrations of donepezil and risperidone in real‐world clinical practice |
| title_full_unstemmed | Effect of concomitant use of yokukansan on steady‐state blood concentrations of donepezil and risperidone in real‐world clinical practice |
| title_short | Effect of concomitant use of yokukansan on steady‐state blood concentrations of donepezil and risperidone in real‐world clinical practice |
| title_sort | effect of concomitant use of yokukansan on steady state blood concentrations of donepezil and risperidone in real world clinical practice |
| topic | drug interactions herb‐drug interactions Kampo metabolism pharmacokinetics |
| url | https://doi.org/10.1002/npr2.12459 |
| work_keys_str_mv | AT junjisaruwatari effectofconcomitantuseofyokukansanonsteadystatebloodconcentrationsofdonepezilandrisperidoneinrealworldclinicalpractice AT tetsuyakaneko effectofconcomitantuseofyokukansanonsteadystatebloodconcentrationsofdonepezilandrisperidoneinrealworldclinicalpractice AT tsukasamurata effectofconcomitantuseofyokukansanonsteadystatebloodconcentrationsofdonepezilandrisperidoneinrealworldclinicalpractice AT harukanarise effectofconcomitantuseofyokukansanonsteadystatebloodconcentrationsofdonepezilandrisperidoneinrealworldclinicalpractice AT sawakugimoto effectofconcomitantuseofyokukansanonsteadystatebloodconcentrationsofdonepezilandrisperidoneinrealworldclinicalpractice AT erinishimura effectofconcomitantuseofyokukansanonsteadystatebloodconcentrationsofdonepezilandrisperidoneinrealworldclinicalpractice AT natsukitetsuka effectofconcomitantuseofyokukansanonsteadystatebloodconcentrationsofdonepezilandrisperidoneinrealworldclinicalpractice AT misakiando effectofconcomitantuseofyokukansanonsteadystatebloodconcentrationsofdonepezilandrisperidoneinrealworldclinicalpractice AT momooi effectofconcomitantuseofyokukansanonsteadystatebloodconcentrationsofdonepezilandrisperidoneinrealworldclinicalpractice AT masakoota effectofconcomitantuseofyokukansanonsteadystatebloodconcentrationsofdonepezilandrisperidoneinrealworldclinicalpractice AT nayumihamada effectofconcomitantuseofyokukansanonsteadystatebloodconcentrationsofdonepezilandrisperidoneinrealworldclinicalpractice AT keiichirokaneda effectofconcomitantuseofyokukansanonsteadystatebloodconcentrationsofdonepezilandrisperidoneinrealworldclinicalpractice AT shirofurusho effectofconcomitantuseofyokukansanonsteadystatebloodconcentrationsofdonepezilandrisperidoneinrealworldclinicalpractice AT masakatsusakamoto effectofconcomitantuseofyokukansanonsteadystatebloodconcentrationsofdonepezilandrisperidoneinrealworldclinicalpractice AT ayamikajiwaramorita effectofconcomitantuseofyokukansanonsteadystatebloodconcentrationsofdonepezilandrisperidoneinrealworldclinicalpractice AT kazutakaoda effectofconcomitantuseofyokukansanonsteadystatebloodconcentrationsofdonepezilandrisperidoneinrealworldclinicalpractice AT kentarooniki effectofconcomitantuseofyokukansanonsteadystatebloodconcentrationsofdonepezilandrisperidoneinrealworldclinicalpractice AT keishiueda effectofconcomitantuseofyokukansanonsteadystatebloodconcentrationsofdonepezilandrisperidoneinrealworldclinicalpractice AT hirofumijono effectofconcomitantuseofyokukansanonsteadystatebloodconcentrationsofdonepezilandrisperidoneinrealworldclinicalpractice AT norioyasuifurukori effectofconcomitantuseofyokukansanonsteadystatebloodconcentrationsofdonepezilandrisperidoneinrealworldclinicalpractice |